BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Moves to Acquire ‘Safety Shot’ – the World’s First Rapid Blood Alcohol Detox Drink

Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness, today announced it has executed an asset purchase agreement with GBB Drink Lab Inc. Under the agreement, all operating assets related to GBB Drink Lab, including the revolutionary Safety Shot beverage, will belong to Jupiter Wellness. Safety Shot, which is protected by a number of issued and pending patents covering composition of matter and methods of use, creates a new product category for rapid alcohol detoxification in the fast-growing hangover remedy market. “The world-first breakthrough nature of Safety Shot and the market it addresses are a tremendous opportunity that Jupiter will effectively execute upon,” said Jupiter Wellness CEO Brian John. “This asset purchase is a truly transformational transaction for the company and its shareholders.”

To view the full press release, visit https://ibn.fm/gTvs4

About Jupiter Wellness Inc.

Jupiter Wellness, a wellness company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sells its products through third-party physical retail stores and partners. The company was formerly known as CBD Brands Inc. Jupiter Wellness Inc. was incorporated in 2018 and is headquartered in Jupiter, Florida. For more information, visit the company’s website at www.JupiterWellness.com.

NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://ibn.fm/JUPW

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Set to Report Q1 Earnings in Wake of HOPE’s Strategic Kadima Agreement

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is scheduled to report its first quarter 2025 financial results…

3 hours ago

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Hits FDA Milestone and Expands Strategic Partnerships in Q1 Update

HeartBeam (NASDAQ: BEAT) reported Q1 2025 results highlighted by successful completion of the VALID-ECG pivotal…

9 hours ago

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Prices $5 Million Public Offering with Institutional Investor

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on brain and central nervous system cancers,…

10 hours ago

BioMedNewsBreaks – Intelligent Bio Solutions Inc. (Nasdaq: INBS) Grows Revenue, Cuts Losses in Fiscal Q3 as Cartridge Sales Drive Margins

Intelligent Bio Solutions (Nasdaq: INBS), a medical technology company delivering rapid, non-invasive testing solutions, reported…

1 day ago

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer for TPI 287 in Brain Cancer Indications

CNS Pharmaceuticals (NASDAQ: CNSP) announced the successful transfer of Orphan Drug Designation from Cortice Biosciences…

1 day ago

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire Kadima Neuropsychiatry Institute

NRx Pharmaceuticals (NASDAQ: NRXP) announced that its wholly owned subsidiary, HOPE Therapeutics(TM), has signed a…

1 day ago